Exelixis, Inc. (EXEL)

jcm56 (91.15) Submitted: 9/22/06 9:04 PM : Start Price: $8.89 EXEL Score: -14.07

Small company with lots of drugs in various clinical phases. As a physician, I feel good about the future prospects of targeted cancer therapies--the improved side-effect profile and molecular specificity just make a whole lot of sense. That being said, this is a stock fraught with peril in the form of hype, the FDA, and assuming lots of things which can't be absolutely known.

On balance, buying this company over the next few years when the price is weak and aiming to hold for at least five to ten years seems like a no-brainer. Most likely, more than one of the current crop of drugs will be commonly used in 2014.

I don't like risky moves in general, but avoiding all risky moves keeps you from hitting it big. The best way to modulate the risk is to plan on holding for the long haul and buying on weakness if you are convinced the company has big potential.

Report this Post Replies: 0 | Reply